IDO1 and cancer: Other clinical trials are evaluating the combination of IDO inhibitors, including epacadostat, navoximod and BMS-986205, with immune checkpoint inhibitors in cancer patients, with early results showing that these combination therapies are well tolerated and have some activity (103, 104).